Ursolic acid against prostate and urogenital cancers: a review of in vitro and in vivo studies

A Kornel, M Nadile, MI Retsidou, M Sakellakis… - International Journal of …, 2023 - mdpi.com
Prostate cancer is the second most diagnosed form of cancer in men worldwide and
accounted for roughly 1.3 million cases and 359,000 deaths globally in 2018, despite all the …

VAV3 in human cancers: Mechanism and clinical implication

SIS Al-Hawary, A Alsalamy, R Gupta, HO Alsaab… - … -Research and Practice, 2023 - Elsevier
Guanine nucleotide exchange factors (GEFs) are primarily involved in signal transmission
between cell membrane receptors and intracellular mediators. Upon replacing GDP with …

Development of novel paclitaxel-loaded ZIF-8 metal-organic framework nanoparticles modified with peptide dimers and an evaluation of its inhibitory effect against …

H Zhao, L Gong, H Wu, C Liu, Y Liu, C Xiao, C Liu… - Pharmaceutics, 2023 - mdpi.com
Prostate cancer (PC) is one of the common malignant tumors of the male genitourinary
system. Here, we constructed PTX@ ZIF-8, which is a metal-organic-framework …

[HTML][HTML] Bromocriptine monotherapy overcomes prostate cancer chemoresistance in preclinical models

L Bai, X Li, Y Yang, R Zhao, EZ White, A Danaher… - Translational …, 2023 - Elsevier
Chemoresistance is a major obstacle in the clinical management of metastatic, castration-
resistant prostate cancer (PCa). It is imperative to develop novel strategies to overcome …

Overexpressed KCNK1 regulates potassium channels affecting molecular mechanisms and biological pathways in bladder cancer

W Zhang, XS Chen, Y Wei, XM Wang, XJ Chen… - European Journal of …, 2024 - Springer
This study aimed to explore the expression, molecular mechanism and its biological function
of potassium two pore domain channel subfamily K member 1 (KCNK1) in bladder cancer …

Discovery and biological evaluation of novel CARM1/HDAC2 dual-targeting inhibitors with anti-prostate cancer agents

S Liang, Y Geng, MM Niu, Y Zhang, W He… - Journal of Enzyme …, 2023 - Taylor & Francis
Prostate cancer (PCa) is a clinically heterogeneous disease with a progressively increasing
incidence. Concurrent inhibition of coactivator-associated arginine methyltransferase 1 …

Targeting sphingosine 1-phosphate metabolism as a therapeutic avenue for prostate cancer

S Mebarek, N Skafi, L Brizuela - Cancers, 2023 - mdpi.com
Simple Summary Prostate cancer (PC) is the most common cancer in men over 65 and the
fifth leading cause of death by cancer in men. Sphingosine 1-phosphate (S1P) is a bioactive …

Novel FOXM1 inhibitor STL001 sensitizes human cancers to a broad-spectrum of cancer therapies

S Raghuwanshi, X Zhang, Z Arbieva, I Khan… - Cell Death …, 2024 - nature.com
Forkhead box protein M1 (FOXM1) is often overexpressed in human cancers and strongly
associated with therapy resistance and less good patient survival. The chemotherapy …

Development and characterisation of suitably bioengineered microfibrillar matrix-based 3D prostate cancer model for in vitro drug testing

AT Thilakan, N Nandakumar… - Biomedical …, 2023 - iopscience.iop.org
Bioengineered 3D models that can mimic patient-specific pathologies in vitro are valuable
tools for developing and validating anticancer therapeutics. In this study, microfibrillar …

Hippo signaling modulation and its biological implications in urological malignancies

T Tong, M Huang, B Yan, B Lin, J Yu, Q Teng… - Molecular Aspects of …, 2024 - Elsevier
Although cancer diagnosis and treatment have rapidly advanced in recent decades,
urological malignancies, which have high morbidity and mortality rates, are among the most …